Comparison between nafarelin acetate andd-Trp6-LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: A prospective crossover study
- 47 Downloads
Nafarelin acetate is a new gonadotropin releasing (GnRH) agonist analogue with unique potency, intranasal administration, and convenient storage. Hence, nafarelin was considered as an alternative for temporary pituitary suppression in patients undergoing ovulation induction in IVF. A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol. Twenty patients used nafarelin acetate 600 Μg/daily in their first cycle and receivedd-Trp6-LHRH, 0.5 mg/daily, in their following cycle. The other 20 women used decapeptyl in their first cycle and received nafarelin in the second.
Estradiol suppression was achieved by bothd-Trp6-LHRH and nafarelin at equal time intervals. The average total number of ampoules (P=0.0005) and the length of administration of hMG required for ovarian stimulation (P=0.0002) and the time interval between GnRHa initiation to oocyte retrieval (P=0.04) was significantly lower in nafarelin cycles. The number and the distribution between large and small follicles as well as the average number of oocytes retrieved did not differ between the two GnRH analogues.
Our results demonstrate that nafarelin acetate is comparable tod-Trp6-LHRH for temporary pituitary suppression used for controlled ovarian stimulation in IVF patients. However, using nafarelin ovarian stimulation was achieved with fewer ampoules of hMG, administered for a shorter period of time, thus with a lesser cost.
Key wordsnafarelin acetate gonadotropin releasing hormone analogues controlled ovarian stimulation in vitro fertilization pituitary suppression
Unable to display preview. Download preview PDF.
- 1.Henzl MR: Gonadotropin-releasing hormone (GnRH) agonists is the management of endometriosis: A review. Clin Obstet Gynecol 1988;31:840–856Google Scholar
- 2.Data on Syntex file (CL 3867)Google Scholar
- 3.Yuzpe AA, Yuzpe E, Kaplan B, Nisker J, Tummon I, Daniel S: A comparison between two doses of nafarelin acetate and leuprolide for pituitary down-regulation in in vitro fertilization. Gynecol Endocrinol 1992;7:Suppl 2 (abstr 72)Google Scholar
- 4.Dantas ZN, Viccino M, Filho EA, Balmaceda JP, Asch RH, Stone SC: Comparison between nafarelin and leuprolide for in vitro fertilization. 41st Annual Meeting of the Pacific Coast Fertility Society, Apr 14–18, 1993, abstract P-004Google Scholar
- 5.Penzias AS, Shamma FN, Gutmann JN, Jones EE, DeCherney AH, Lavy G: Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: A randomized clinical trial. Obstet Gynecol 1992;79:739–742Google Scholar
- 6.Lopes P, Barriere P, Julou V, Dubin MF, Benelli M, Jean M, Orylavollee L: A randomized comparison of nafarelin nasal spray and triptorelin S.C. in a short protocol of stimulation prior to IVF. Gynecol Endocrinol 1992;7:Suppl 2 (abstr 70)Google Scholar
- 7.Alvarez S, Lelaider C, Cataneo A, Hedon B, Frydman R, Salat-Baroux J, Ory-Lavollee L: A randomized multicenter comparison between nafarelin nasal spray and buserelin SC for down-regulation prior to ovarian stimulation in an IVF program. Gynecol Endocrinol 1992;7:Suppl 2 (abstr 71)Google Scholar
- 8.Lockwood GM, Barlow DH: A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long protocol GnRH analogue controlled IVF treatment. Gynecol Endocrinol 1992;7:Suppl 2 (abstr 69)Google Scholar
- 9.Goldman JA, Dicker D, Feldberg D, Ashkenazi J, Voliowich I: A prospective randomized comparison of two gonadotropin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in-vitro fertilization-embryo transfer. Hum Reprod 1994;9:226–228Google Scholar